These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2544127)

  • 1. Pharmacokinetics of heparin and related polysaccharides.
    Boneu B; Dol F; Caranobe C; Sie P; Houin G
    Ann N Y Acad Sci; 1989; 556():282-91. PubMed ID: 2544127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
    Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B
    Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of dermatan sulfate in the rabbit after intravenous injection.
    Dol F; Houin G; Dupouy D; Cadroy Y; Caranobe C; Gabaig AM; Mardiguian J; Sié P; Boneu B
    Thromb Haemost; 1988 Apr; 59(2):255-8. PubMed ID: 3388296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
    Briant L; Caranobe C; Saivin S; Sié P; Bayrou B; Houin G; Boneu B
    Thromb Haemost; 1989 Jun; 61(3):348-53. PubMed ID: 2552603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of heparin and low molecular weight heparin.
    Boneu B; Caranobe C; Sie P
    Baillieres Clin Haematol; 1990 Jul; 3(3):531-44. PubMed ID: 2176903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits.
    Boneu B; Buchanan MR; Caranobe C; Gabaig AM; Dupouy D; Sie P; Hirsh J
    Thromb Res; 1987 Jun; 46(6):845-53. PubMed ID: 3629551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits.
    Boneu B; Caranobe C; Gabaig AM; Dupouy D; Sie P; Buchanan MR; Hirsh J
    Thromb Res; 1987 Jun; 46(6):835-44. PubMed ID: 3629550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits.
    Ishida M; Nakada Y; Horiuchi M; Sakamoto F
    Arzneimittelforschung; 1998 Aug; 48(8):818-21. PubMed ID: 9748709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
    Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans.
    Dol F; Houin G; Rostin M; Montastruc JL; Dupouy D; Gianese F; Sie P; Boneu B
    Blood; 1989 Oct; 74(5):1577-82. PubMed ID: 2790187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
    Abrial D; Blanc A; Réhailia M; Mismetti P; Bouchut C; Laporte-Simitsidis S; Decousus H; Buisson B
    Haemostasis; 2000; 30(5):233-42. PubMed ID: 11251330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic properties of long lasting butyryl heparin derivatives in the rabbit.
    Saivin S; Caranobe C; Petitou M; Lormeau JC; Houin G; Boneu B
    Thromb Haemost; 1992 May; 67(5):550-5. PubMed ID: 1325682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.
    Carrie D; Caranobe C; Gabaig AM; Larroche M; Boneu B
    Thromb Haemost; 1992 Dec; 68(6):637-41. PubMed ID: 1287877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties.
    Dol F; Caranobe C; Dupouy D; Petitou M; Lormeau JC; Choay J; Sié P; Boneu B
    Thromb Res; 1988 Oct; 52(2):153-64. PubMed ID: 3194890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of low molecular weight heparins.
    Bara L; Samama M
    Acta Chir Scand Suppl; 1988; 543():65-72. PubMed ID: 2847460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The haemorrhagic and antithrombotic effects of dermatan sulphate.
    Fernandez F; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
    Br J Haematol; 1986 Oct; 64(2):309-17. PubMed ID: 3778825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
    Danhof M; de Boer A; Magnani HN; Stiekema JC
    Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of dermatan sulfate in vitro and in vivo by protamine sulfate and polybrene.
    Sié P; Cremers B; Dupouy D; Caranobe C; Dol F; Boneu B
    Thromb Res; 1989 Apr; 54(1):63-74. PubMed ID: 2727957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.